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A large numbers of cell surface signaling molecules (CSSMs) have been molecularly identified and function-
ally characterized in recent years and, via these studies, our knowledge in the control of immune response
has increased exponentially. Two major lines of evidence emerge. First, the majority of immune cells rely
on one or few CSSMs to deliver a primary triggering signal to sense their environment, leading to initiation
of an immune response. Second, both costimulatory CSSMs that promote the response, and coinhibitory
CSSMs that inhibit the response, are required to control direction and magnitude of a given immune
response. With such tight feedback, immune responses are tuned and returned to baseline. These findings
extend well beyond our previous observation in the requirement for lymphocyte activation and argue a revisit
of the traditional ‘‘two-signal model’’ for activation and tolerance of lymphocytes. Here we propose a ‘‘tide’’
model to accommodate and interpret current experimental findings.Introduction
All immune cells, including those participating in the innate and
adaptive immune response, have evolved to express distinct
cell surface receptors or ligands to sense and respond to
environmental cues. These cell surface signaling molecules
(CSSMs) are vital for differentiation, recognition, and cellular
function. Many cell types consistently monitor the dynamic envi-
ronmental stimuli through their unique receptors to recognize
specific changes. For example, a specific T cell receptor (TCR)
binds a major histocompatibility complex (MHC)-peptide struc-
ture on a professional antigen-presenting cell (APC). This TCR
transmits an antigenic signal, initiating the downstream signaling
pathways of an immune response (Smith-Garvin et al., 2009).
APCs also respond to changes in their surrounding environ-
mental stimuli using toll-like receptors (TLRs) to identify potential
pathogens (Palm andMedzhitov, 2009). Natural killer cells (or NK
cells) utilize natural cytotoxicity receptors (NCRs) to recognize
changes on target cells caused by viral infections or stress
(Lanier, 2005). High-affinity IgE receptors on mast cells
contribute to immune detection and surveillance by identifying
allergen-IgE complexes (Sayed et al., 2008). Therefore, immune
cells utilize these receptors to transmit an initial signal to turn on
the immune response.
For years immunologists have sought to understand the
mechanisms of antigen-specific immune responses and the
versatile nature of antigen receptors on the surface of lympho-
cytes.With the attempt to produce a cellularmodel incorporating
the theory of self and nonself discrimination, Bretscher and Cohn
were the first to propose a two-signal model to account for B cell
tolerance induction (Bretscher and Cohn, 1970). Later this model
was extended and applied to T lymphocytes by Lafferty,
Schwartz, and colleagues (Lafferty and Cunningham, 1975;
Mueller et al., 1989).The two-signal model explains why lympho-
cytes are only partially activated or even unresponsive after
exposure to Signal 1 from antigen-receptor. Only after exposure
to a second, costimulatory cell surface signal does full activation466 Immunity 34, April 22, 2011 ª2011 Elsevier Inc.of the lymphocyte occur (Lafferty and Cunningham, 1975).
Further experiments revealed a molecular identity for the costi-
mulatory signal (also called Signal 2): the CD28-CD80 interaction
(Linsley et al., 1990). Since then, the two-signal model has
gained increasing experimental support, contributing to our
understanding of lymphocyte activation.
The last decade has witnessed dramatic progress in the iden-
tification and characterization of CSSMs, largely due to the
completion of the human genome project. More than 4000
molecules have been identified as potential CSSMs, based on
similarities in their transmembrane protein structure, along with
their signature intracellular and extracellular domains (Lander
et al., 2001; Venter et al., 2001). A group of these CCSMs have
been functionally characterized, giving new perspectives on
the regulation of immune responses and translating to the clinic
new therapeutic treatments of human disease. Studies charac-
terizing the role of individual immune cells and their specific
type of immune responses have revealed several large gene
families that provide critical signals in immune cell activation,
including tumor necrosis factor (TNF), immunoglobulin (Ig), G
protein-coupled receptor (GPCR), and the lectin receptor family
(i.e., Siglec, Dectin, DNGR-1, DC-SIGN, etc.). In this review, we
propose a comprehensive ‘‘tide’’ model to bridge the gap that
exists between our current knowledge of specific immune cell
regulation and how the complex, downstream, multicellular
immune response is regulated and controlled by CSSMs.
Rationales for the Revision of the Two-Signal Model
Our understanding of T lymphocyte activation has been
profoundly influenced by the ‘‘two-signal model’’ in which costi-
mulation provided by ‘‘Signal 2’’ is necessary for optimal activa-
tion of lymphocytes. Functional analyses indicate that CSSMs
are not only costimulatory but also coinhibitory (Greenwald
et al., 2005). Importantly, expression of these coinhibitory mole-
cules is often induced de novo or upregulated upon T cell activa-
tion in the presence of costimulation, indicating a negative
Figure 1. The Tide Model for the Control of Immune Response
We define the primary signal as a triggering signal that is initiated by specific
binding of ligand to its receptor (R) on immune cells. The primary signal selects
and/or marks the cells but is not sufficient to induce a biologically significant
‘‘Response’’ such as phosphorylation of the receptor or the receptor complex.
In the absence of cosignals, the primary signal normally does not decide the
direction and magnitude of a cellular response. The cosignals, which could be
either costimulatory or coinhibitory, are modulators of the primary signal and
could decide the directions and magnitude of a cellular reaction. The primary
signal could either induce ‘‘Response’’ when costimulatory signal is dominant
or trigger ‘‘Un-Response’’ in the presence of dominant coinhibitory signal. With
a strong far-reaching coinhibitory signal, even an initial ‘‘Response’’ could be
terminated (‘‘De-response’’). Similarly, a strong costimulatory signal may also
reverse ‘‘Un-response’’ to ‘‘Response.’’ It is worth noting that a ‘‘Response’’
does not always lead to activation of an immune response. For example,
a ‘‘Response’’ of regulatory T cells often suppresses immune response while
the ‘‘Response’’ of CD25-FoxP3-CD4+ T cells may enhance an immune
response. With such tight control of cosignals, all cellular response will have
a rise-and-fall pattern like the tide.
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these coinhibitory molecules in mouse models often leads to
various autoimmune diseases associated with overactive T cell
responses (Chen, 2004), demonstrating the indispensible role
of coinhibitors in in vivo T cell tolerance induction. Therefore,
although the TCR signal is essential and required for the selec-
tion and initial triggering of T cell responses, it is often the cosig-
nal that dictates the outcome of a T cell response, including both
activation and tolerance. Additionally, nearly all immune cells
including NKT cells, NK cells, gd T cells, macrophages, dendritic
cells (DCs), monocytes, and mast cells (besides T and B cells)
also have been shown to have similar requirements for a primary
triggering signal (Signal 1- like), and ample experimental data
demonstrate that CSSMs are present on these cell types and
are able to modulate and fine tune their responses.
The ‘‘Tide’’ Model
Left unchecked, uncontrolled inflammatory immune responses
are dangerous to the host; therefore, under this hypothesis the
necessary immune components and the resulting inflammatory
responses are tightly controlled to limit or avoid excess damage
to the surrounding tissue. Here we propose a new tide model of
immunity that incorporates our current molecular understanding
of an immune response (Figure 1) and provides additional insight
into both innate and adaptive immunity. In this model, we define
primary signal as the initiator of specific immune cells reacting to
extracellular stimuli. Meanwhile, the cosignals, either costimula-
tory or coinhibitory, are modulators that decide the direction andmagnitude of the immune response. The characteristics of this
self-feedback, tide signal model are outlined below.
First, the role of primary signal is extended to include
a broader, more intricate function in immunity, spreading beyond
its current activity through TCR and BCR to include initiating
a cascade of activation or deactivation on all immune cells during
both innate and adaptive immune responses.
Second, primary signal is the initiator, but primary signal itself
does not decide the fate of the immune response. Primary signal
is received by the receptors on certain immune cell types; then
these cells can induce several early downstream biochemical
signaling events. However, it is the cosignals that determine
the overall outcome of the immune response.
Third, cosignals include signals with stimulatory function (cos-
timulator) as well as that with inhibitory function (coinhibitor).
While a costimulatory signal is required to optimize an immune
response, the coinhibitory signal is often induced and triggered
by primary signal together with a costimulator, thus serving as
a strong negative feedback signal. Therefore, we use ‘‘tide’’ to
describe the rise and fall of immune response due to interplay
of these signals.
Finally, cosignaling molecules are highly diverse in abilities to
monitor and control immune cell responses. The expression of
cosignaling molecules is differentially and tightly regulated
through every stage and location of immune cell activation.
They transduce signals through a series of cosignaling path-
ways. In addition, the nature of individual cosignaling molecules
determines its preferential participation in one or more functional
aspects of immune cell activation.
Signal 1 and Cosignals for Immune Cell Subsets
Each cell type bears different ‘‘recognizing’’ receptors for
primary signal, and signaling through these receptors is very
distinct (Figure 2). As for cosignaling molecules, a lot of them
are shared among several cell types while some are uniquely
present on certain cell types (Table 1).
ab T Lymphocytes
T lymphocytes are the essential components for adaptive
immune responses. ab T lymphocytes constitute 98% of total
T cells. T cells represent the cell type that has been most
comprehensively and extensively studied with regard to the
role of cosignals. In addition to CSSMs, cytokines, such as inter-
leukin-12 (IL-12), transforming growth factor-b (TGF-b), and IL-6,
are crucial for further differentiation of T cells, especially CD4+ T
helper cells, though the role of cytokines as cosignals is beyond
the scope of this review.
Primary signal for conventional T cells is mediated through
TCR engagement. Conventional T cells carrying the ab TCR
recognize small antigenic peptides presented in the groove of
the self major histocompatibility complex (MHC). As a result of
this recognition, TCR complexes aggregate on T cell surfaces
to form stable contacts resulting in the formation of immunolog-
ical synapses on APC (Huppa and Davis, 2003). Early intracel-
lular signaling, following TCR engagement involves the activation
of Src (Lck and Fyn) protein tyrosine kinases (PTKs), leading to
the phosphorylation of CD3-localized immunoreceptor tyro-
sine-based activation motifs (ITAMs). Subsequently, the PTK
ZAP-70 is recruited, resulting in a series of phosphorylation
events (Smith-Garvin et al., 2009).Immunity 34, April 22, 2011 ª2011 Elsevier Inc. 467
Figure 2. Cell Surface Signaling Molecules in the Control of Immune Responses
The major primary signal and cosignal (costimulatory or coinhibitory) molecules are shown in each immune cell type. TLR, Toll-Like Receptor; RLR, RIG-like
Receptors; NLR, NOD-like Receptor.
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stem from the B7 family and TNF superfamily of receptors
(Table 1). In addition to interactions between CD28 and CTLA-
4 receptors with their ligand B7-1 (CD80) and B7-2 (B70,
CD86) (Greenwald et al., 2005), several recent studies add new
perspectives for this classic pathway. B7-1 has been found to
interact with B7-H1. In this case, B7-1 serves as a receptor to
inhibit T cell responses in vitro (Butte et al., 2007) and contributes
to the induction of T cell tolerance in vivo (Park et al., 2010).
B7-H2, a molecule best known as the ligand for Inducible Costi-
mulator (ICOS), is found to be a costimulatory ligand for CD28
in vitro (Yao et al., 2011). Interestingly, this interaction is only
found in human, not in mouse, warranting re-evaluation of data
previously obtained from mouse models. Herpesvirus entry
mediator (HVEM), a member of the TNF receptor (TNFR) super-
family, is commonly recognized as a costimulatory receptor for
LIGHT (TNFSF14) and lymphotoxin- a (Xu et al., 2007). Interest-
ingly, HVEM has recently been found to interact with B and
T lymphocyte attenuator (BTLA) and CD160, and deliver a
suppressive signal to T cells (Cai et al., 2008; Watanabe et al.,
2003). The complex molecular network between HVEM and its
binding partners makes bidirectional signaling feasible and468 Immunity 34, April 22, 2011 ª2011 Elsevier Inc.reveals surprising cross-talk between TNFR superfamilies and
Ig-like receptors. In addition to the B7 and TNF families, several
new families of molecules have emerged with potent cosignaling
function, including T cell immunoglobulin domain and mucin
domain (TIM) family, poliovirus receptor (PVR)-like proteins (Bot-
tino et al., 2003; Xu and Jin, 2010; Yu et al., 2009), semaphorins
(Kumanogoh et al., 2002; Takegahara et al., 2006; Wen et al.,
2010), and butyrophilin-like molecules (Nguyen et al., 2006;
Smith et al., 2010; Stefferl et al., 2000).
WhydoTcells need somanycosignals?One simple answer for
this question is that T cell activation is an instructively pro-
grammed process and every step of a T cell response is tightly
controlled by many different groups of cosignaling molecules
with both costimulatory and coinhibitory functions. A typical
T cell response evolves at least three steps: priming, expansion,
and contraction. Costimulators, such as CD27, CD28, and
HVEM, which are constantly expressed on naive T cells, are
known to be important initiators for naive T cell activation in
lymphoid organs in the presence of a TCR signal (Sharpe, 2009;
Watts, 2005), while the majority of coinhibitory receptors are
undetectable during this period. Further expansion of such
T cells requires signals through ICOS, death receptor 3 (DR3),
Immunity
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ligands are available in lymphoid organs, coinhibitory molecules
like CTLA-4, PD-1, BTLA, and LAG-3 are now unregulated and
make activated T cells susceptible to negative control (Chen,
2004; Murphy et al., 2006; Okazaki et al., 2011). This could be
considered the first level of negative control. For example,
expression of B7-H1 is found to be upregulated in lymph nodes,
upon interacting with PD-1, leading to tolerance induction of
T cells (Tsushima et al., 2007). Upon exit from lymphoid organs
and arrival into the periphery, effector T cells begin to execute
their functions. OX40 and CD137 have proven to be critical for
effector T cell survival and therefore memory T cell generation
(Watts, 2005). During and after execution of effector functions,
effector T cells are subjected to another level, and possibly the
most severe negative regulation. Peripheral organs and tissues
are equipped with various coinhibitory ligands including B7-H1,
B7-H4, Galectin-9, PVR, Semaphorins, V-set, and immunoglob-
ulin domain containing 4 (VSIG4) (Vogt et al., 2006) and butylo-
phines, which are ready to either tune down or terminate effector
T cells. Therefore, different cosignaling molecules may form
distinct groups to regulate various stages of T cell activation.
Diverse expression of cosignaling molecules also allows
differential control of T cell subsets and their ‘‘personalized’’
characters are critical to modulating immune responses. For
example, CD137 is a potent costimulator for CD8+ T cells, while
its effects on CD4+ T cell are less profound (Watts, 2005). On the
contrary, OX40 and ICOS are found to preferentially costimulate
CD4+ over CD8+ T cells despite the fact that they are induced on
both activated CD4+ and CD8+ T cells (Greenwald et al., 2005;
Watts, 2005). These results suggest an intrinsic difference
between CD4+ and CD8+ T cells in responding to cosignals.
Another example is that, although both CTLA-4 and PD-1 are
coinhibitory for effector T cells, blockage of PD-1 signal, but
not CTLA-4, restores the function of exhausted T cells, thereby
reducing viral load during chronic viral infection (Barber et al.,
2006). This would support the concept that PD-1 selectively
controls the exhaustion phenotype. In many cases, distinct
expression patterns of cosignaling molecules have selective
effects on T cell subsets. Both B7-DC and B7-H1 deliver an
inhibitory signal to T cells through their shared receptor PD-1
(Chen, 2004). The expression of B7-DC is restricted to profes-
sional APCs such as DCs. In contrast, B7-H1 mRNA is present
in almost all peripheral tissues and cell surface protein expres-
sion is extremely sensitive to the regulation by proinflammatory
cytokines (Chen, 2004). As a result, the role of B7-DC is limited
to T cell priming, while the role of B7-H1 on T cells could be
broad: acting on both priming and effector phases.
CD28 is constitutively present on T cells, providing instant help
to potential T cell activation. Meanwhile, its counterpart, CTLA-4,
is mainly found in intracellular reservoirs, which allows CTLA-4 to
rapidly transport to the cell surface in response to antigenic
stimuli and to exert its immune-modulatory function (Schneider
et al., 2006). Interestingly, CTLA-4 is constitutively present on
the surface of fox-head box protein 3 (Foxp3)+ regulatory T
(Treg) cells and is required for the maintenance of Treg cell func-
tion in vivo (Wing et al., 2008). Meanwhile the coinhibitory PD-1
protein is not expressed on naive T cells yet is transiently
induced on activated T cells (Chen, 2004). However, PD-1 is
highly expressed on T cells with exhausted phenotypes, inducedby constant exposure to antigen stimuli during chronic viral
infection or malignancy. Blockade of the PD-1 pathway restores
T cell function, emphasizing the critical role of PD-1 in T cell
dysfunction during chronic viral infection (Barber et al., 2006).
Thus, the expression pattern of each cosignaling molecule
contributes greatly to their differential regulatory functions.
Our understanding of how intracellular biochemical pathways
transmit cosignals is still rudimentary. This is largely due to an
absolute dependence of cosignal function on TCR-mediated
signaling. Given the overlapping but distinctive function of
cosignals, it is not difficult to understand that cosignaling
molecules regulate T cell immunity utilizing both shared and
unique signaling pathways. The most straightforward strategy
is to consider intracellular motifs from each cosignaling receptor.
One common pathway for CD28 and its familymembers, such as
ICOS and CTLA-4, is the recruitment of class 1A forms of phos-
phatidylinositol 3-kinase (PI3K) to their cytoplasmic domains
(Rudd and Schneider, 2003). Unlike CD28, ICOS lacks the intra-
cellular motif to bind growth-factor receptor-bound protein 2
(GRB2), which might contribute to its ineffective induction of
IL-2 production (Rudd and Schneider, 2003). Coinhibitory
receptors such as PD-1 and BTLA utilize the immunoreceptor
tyrosine-based inhibitory motif (ITIM) to recruit SRC homology
2 (SH2)-domain-containing protein tyrosine phosphatase 2
(SHP-2) or SHP-1 and SHP-2, which dephosphorylates and
therefore deactivates downstream signal transducers
(Greenwald et al., 2005; Watanabe et al., 2003). Cosignaling
receptors from the TNFR superfamily contain the intracellular
regions necessary for interacting with TNFR-associated
factors (TRAFs) (Croft, 2009). TRAFs can recruit inhibitors of
nuclear factor-kB (NF-kB), a subunit (IkBa), IkB kinase-b (IKKb),
and NF-kB-inducing kinase (NIK), leading to the activation of
both canonical and noncanonical NF-kB pathways that are
essential for cell survival (Vallabhapurapu and Karin, 2009).
Several TNFRcoreceptors also activate signalingpathwaysother
than NF-kB, which might not be shared among TNFR members
but contribute to their regulatory functions. For instance, ligation
of CD137 activates extracellular-signal-regulated kinase (ERK)
and regulates theexpression of cyclins (Watts, 2005).Meanwhile,
signaling through the TNFR OX40 promotes the expression of
survivin and aurora B kinase (Sugamura et al., 2004).
There are numerous studies detailing the coordination of
cosignals with TCR signals (Sharpe, 2009; Smith-Garvin et al.,
2009). Engagement of TCR regulates the expression of several
cosignaling molecules on T cells, and the strength of Signal 1
presumably affects the recruitment of cosignaling molecules to
the immune synapse (Egen and Allison, 2002). TCR ligation alone
can trigger many signaling pathways; however, the magnitude of
the response is considerably altered in the presence of cosignal-
ing molecules. It appears that engagement of cosignaling mole-
cules results primarily in a quantitative, rather than a qualitative,
change in T cell signaling parameters (Smith-Garvin et al., 2009).
gd T Lymphocytes
gd T cells represent a small subset of T cells that possess
a unique TCR and preferentially reside within epithelial-rich
tissues, such as the skin, intestine, and reproductive tracts. gd
T cells recognize conserved nonpeptide antigens that are upre-
gulated by stressed cells in an MHC-independent manner. The
physiological roles of gd T cells include protective immunityImmunity 34, April 22, 2011 ª2011 Elsevier Inc. 469
Table 1. Signal 1 and Cosignals for Immune Cell Subsets
Cell type Signal 1 Cosignals Receptor Ligand(s) Intracellular Signaling Reference(s)
T cell (ab)
TCR Costimulator CD28 B7-1, B7-2, B7-H2 (h)* PI3K, GRB2, Vav (Rudd and Schneider, 2003)
ICOS B7-H2 PI3K (Rudd and Schneider, 2003)
TLT2? B7-H3 - (Hashiguchi et al., 2008;
Leitner et al., 2009)
- B7-H1, B7-DC - (Wang et al., 2003)
CD27 CD70 NF-kB, Bcl2 (Watts, 2005)
CD137 CD137L NF-kB, Bcl-2,Erk (Watts, 2005)
OX40 OX40L NF-kB, Bcl-2, PI3K (Watts, 2005)
Survivin (Watts, 2005)
HVEM LIGHT NF-kB (Mauri et al., 1998)
DR3 TL1A NF-kB (Migone et al., 2002)
NKG2D MICA, MICB DAP-10 (Moretta et al., 2001)
ULBP-4, RAET1G (Moretta et al., 2001)
TIM-1 TIM-4,
phosphatidylserine
- (Meyers et al., 2005;
Miyanishi et al., 2007)
TIM-2 H-Ferritin, Sema4A? - (Chen et al., 2005;
Kumanogoh et al., 2002)
DNAM-1 PVR, PVRL2 - (Bottino et al., 2003)
CRTAM Necl2 Scrib (Takeuchi et al., 2009)
Coinhibitor CTLA-4 B7-1, B7-2, B7-H2 (h)* PI3K, SHP-2, PP2A (Rudd and Schneider, 2003)
PD-1 B7-H1, B7-DC SHP-2 (Fife et al., 2009)
B7-1 B7-H1 - (Butte et al., 2007; Park et al.,
2010)
- B7-H3 - (Chapoval et al., 2001)
- B7-H4 - (Sica et al., 2003)
BTLA HVEM SHP-1, SHP-2 (Watanabe et al., 2003)
CD160 HVEM - (Cai et al., 2008)
LAG-3 MHC II - (Huard et al., 1994)
TIM-3 Galectin-9,
phosphatidylserine
Ca2+ (Nakayama et al., 2009;
Zhu et al., 2005)
TIGIT PVR, PVRL2, PVRL3 - (Yu et al., 2009)
LAIR-1 Collagen SHP-1, SHP-2 (Lebbink et al., 2006)
- VSIG4 - (Vogt et al., 2006)
- Sema3A - (Wen et al., 2010)
- BTNL1 - (Bas et al., 2011)
- BTNL2 - (Nguyen et al., 2006)
- BTN1A1 - (Smith et al., 2010)
- BTN2A2 - (Smith et al., 2010)
T cell (gd)
TCR Costimulator NKG2D MICA, MICB DAP-10 (Whang et al., 2009)
CAR JAML PI3K (Verdino et al., 2010;
Witherden et al., 2010)
CD137 CD137L NF-kB, Bcl-2,Erk (Zhou et al., 1994)
NKT
iTCR Costimulator CD28 B7-1, B7-2 PI3K, GRB2, Vav (van den Heuvel et al., 2011)
ICOS B7-H2 PI3K (van den Heuvel et al., 2011)
CD40 CD40L TRAF2, 5, 6, JNK, p38 (van den Heuvel et al., 2011)
OX40 OX40L NF-kB, Bcl-2, PI3K (van den Heuvel et al., 2011)
CD137 CD137L NF-kB, Bcl-2,Erk (van den Heuvel et al., 2011)
TIM-1 TIM-4, phosphatidylserine - (van den Heuvel et al., 2011)
470 Immunity 34, April 22, 2011 ª2011 Elsevier Inc.
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Table 1. Continued
Cell type Signal 1 Cosignals Receptor Ligand(s) Intracellular Signaling Reference(s)
Coinhibitor PD-1 B7-H1, B7-DC SHP-2 (van den Heuvel et al., 2011)
BTLA HVEM SHP-1, SHP-2 (van den Heuvel et al., 2011)
GITR GITRL - (van den Heuvel et al., 2011)
B Cell
BCR Costimulator CD40 CD40L, C4BP TRAF2, 5, 6, JNK, p38 (Grewal and Flavell, 1998)
HVEM LIGHT NF-kB? (Duhen et al., 2004)
CD137 CD137L NF-kB? (Zhang et al., 2010)
CD27 CD70 NF-kB (Kobata et al., 1995)
BAFF-R BAFF NF-kB2,
PI3K-Akt1-mTOR
(Mackay and Schneider,
2009)
TACI BAFF, APRIL NF-kB1, MyD88 (Mackay and Schneider,
2009)
BCMA BAFF, APRIL NF-kB (Mackay and Schneider,
2009)
CD72 CD100 Grb2/CD19-PI3K (Kumanogoh et al., 2000)
Coinhibitor PD-1 B7-H1, B7-DC SHP-2 (Good-Jacobson et al., 2010;
Okazaki et al., 2001)
BTLA HVEM SHP-1 (Vendel et al., 2009)
CD72 CD100 SHP-1 (Kumanogoh et al., 2000)
CD22 Sialic acid SHP-1 (Kawasaki et al., 2010)
NK Cell
NKG2D Costimulator DNAM-1 PVRL2, PVR - (Tahara-Hanaoka et al.,
2004)
NKp30 CD96 PVR - (Xu and Jin, 2010)
NKp44 CD137 CD137L - (Wilcox et al., 2002)
NKp46 CD27 CD70 - (Takeda et al., 2000)
2B4 CD48 SAP (Vivier et al., 2011)
NTB-A NTB-A SAP (Vivier et al., 2011)
CRACC CRACC SAP/EAT-2 (Vivier et al., 2011)
Coinhibitor LAIR-1 Collagen SHP-1, 2 (Lebbink et al., 2006)
Siglec-3.7.9 Sialic acid SHP-1, 2 (Avril et al., 2004;
Herna´ndez-Caselles et al.,
2006)
PD-1 B7-H1, B7-DC SHP-2 (Alvarez et al., 2010)
KLRG1 Cadherins SHP-1, 2 (Vivier et al., 2011)
NKR-P1A CLEC2D SHP-1, 2 (Vivier et al., 2011)
ILT2 HLA class I SHP-1, 2 (Vivier et al., 2011)
KIR2DL1,2,3 HLA-C SHP-1, 2 (Vivier et al., 2011)
KIR3DL1,2 HLA-A/B SHP-1, 2 (Vivier et al., 2011)
CD94-NKG2A HLA-E SHP-1, 2 (Vivier et al., 2011)
2B4 CD48 EAT-2, Csk (Moretta et al., 2001)
Myeloid Cells (DCs, Macrophages, Monocytes)
TLR Costimulator B7-1, B7-2 CD28 p38, MAPK (Orabona et al., 2004)
RLR Plexin-A1 Sema6D TREM2-DAP12 (Takegahara et al., 2006)
NLR Plexin-A4 Sema3A Rac1 (Wen et al., 2010)
CD137 CD137L Stat 3 (Vinay and Kwon, 2011)
CD40 CD40L NF-kB (Kikuchi et al., 2000)
CD300b,e - DAP12, Grb2 (Clark et al., 2009)
TREM1,2,3 - DAP12 (Ford and McVicar, 2009)
Coinhibitor ILT7 BST2 Fc3RIg (Brown et al., 2004)
(Continued on next page)
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Table 1. Continued
Cell type Signal 1 Cosignals Receptor Ligand(s) Intracellular Signaling Reference(s)
ILT3,4 - SHP-1,2 (Brown et al., 2004)
TLT-1 - SHP-1,2 (Ford and McVicar, 2009)
CD200R CD200 Dok1, Dok2 (Hoek et al., 2000)
PD-1 B7-H1, B7-DC JNK, PI3K (Said et al., 2010)
TAM family GAS6/protein S SOCS1, SOCS3 (O’Neill, 2007)
CD300a,f - SHP-1,2 (Clark et al., 2009)
DC-SIGN Carbohydrate Raf-1 (Gringhuis et al., 2007)
B7-1, B7-2 CTLA-4 Stat1, p38, MAPK (Grohmann et al., 2002)
Mast Cell
Fc3RI Costimulator Kit SCF SHC, Grb2, PI3K, PLCg (Sayed et al., 2008)
CD137 CD137L Lyn (Sayed et al., 2008)
CD28 B7-1, B7-2 Syk (Sayed et al., 2008)
DNAM-1 PVR, PVRL2 Fyn, LAT, PLCg2 (Sayed et al., 2008)
CD300b TIM-1 DAP12 (Yamanishi et al., 2010)
Coinhibitor Allergin-1 - SHP-1,2 (Hitomi et al., 2010)
Pir-B MHC class I SHP-1.2 (Uehara et al., 2001)
Gp49B1 - SHP-1,2 (Sayed et al., 2008)
CD300a - SHP-1,2 (Bachelet et al., 2005)
‘‘-’’ indicates that it is unknown. ‘‘*’’ indicates that the interaction is human-specific. ‘‘?’’ indicates that the interaction is controversial.
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(Bonneville et al., 2010). gd T cells do not express CD28 or
ICOS, and the role of cosignaling in gd T cell activation has
only recently been investigated. NKG2D, which is known to cos-
timulate CD8+ ab T cell, promotes the cytotoxicity and IL-2
secretion of gd T cells (Whang et al., 2009). Another important
cosignaling pathway for gd T cells is the junctional adhesion
molecule-like protein (JAML)-coxsackie and adenovirus
receptor (CAR) pair (Verdino et al., 2010; Witherden et al.,
2010). The JAML protein is selectively expressed on gd T cell,
but not on ab T cells. Signaling through JAML costimulates gd
T cell proliferation and cytokine production, presumably through
recruitment and activation of PI3K (Verdino et al., 2010). In vivo
blockade of JAML-CAR interaction results in diminished gd
T cell activation and therefore delayedwound healing (Witherden
et al., 2010).
B Lymphocytes
B lymphocytes are the central mediators of humoral responses.
The generation of plasma cells and long-lived memory B cells is
a tightly regulated process, which involves an ordered series of
molecular and cellular changes in vivo. Upon encountering
antigen, B cells rapidly proliferate and undergo class switching
and somatic hypermutation (McHeyzer-Williams and
McHeyzer-Williams, 2005). This process usually happens in the
germinal centers and requires cellular coordinative interactions
among follicular DCs, helper T cells, and B cells (McHeyzer-Wil-
liams and McHeyzer-Williams, 2005). In addition to cytokines,
CSSMs are known to be critical for B cell activation, as originally
proposed in the two-signal model (Bretscher and Cohn, 1970).
The primary signal for B cells is mediated through the B cell
receptor (BCR), which is a multiprotein complex containing
a membrane-bound Ig for antigen-binding and two noncova-
lently associating elements (Ig-a and Igb) for signal transduction472 Immunity 34, April 22, 2011 ª2011 Elsevier Inc.(Kurosaki et al., 2010). Upon antigen binding, BCR signals are
initiated by SRC family kinases, like Lyn, which phosphorylate
ITAMs on the BCR complex, thereafter recruiting and phosphry-
lating Syk (spleen tyrosine kinase). Subsequently, a series of
signaling cascades are triggered, which include the PI3K
pathway, the activation of phospholipase-C g2 (PLCg2), and
the increase of intracellular calcium, all of which change cellular
metabolism, gene expression, and cytoskeleton organization.
However, the complexity of BCR signaling itself permits many
distinct outcomes, which include anergy, apoptosis, prolifera-
tion, and differentiation into plasma cells or memory B cells
(Kurosaki et al., 2010). Similar to T cells, the ultimate outcome
of the response is largely controlled by signals from CSSMs.
Currently, members of the TNFR superfamily are dominant in
delivering costimulatory signals to B cells. Among them, many
costimulatory pathways also provide cosignal for T cells,
including CD27-CD70, CD137-CD137L, and HVEM-LIGHT inter-
actions (Duhen et al., 2004; Kobata et al., 1995; Zhang et al.,
2010). The CD40-CD40L pair is the best-studied pathway and
plays an indispensable role in T cell-dependent B cell responses
(Grewal and Flavell, 1998). CD40 ligation stimulates B cell prolif-
eration, survival, isotype switching, formation of the germinal
center (GC), and memory B cell generation. Mice deficient in
CD40L or CD40 are unable to generate a primary or a secondary
antibody response to a T cell-dependent antigen; do not form
GCs; and are deficient in generating antigen-specific memory
B cells (Grewal and Flavell, 1998). CD40 signaling in B cells leads
to the recruitment of TRAFs, thereafter leading to the activation
of NF-kB and the MAP kinases JNK and p38. BAFF (B cell
activating factor belonging to the TNF family), together with its
close homolog APRIL (a proliferation inducing ligand), are key
regulators for B cell homeostasis (Mackay and Schneider,
2009). In addition to their crucial roles in B cell development
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tion. BAFF and APRIL both bind to TACI (transmembrane
activator and CAML interactor) and BCMA (B cell maturation
protein A), and BAFF also interacts with BAFF receptor (BAFFR).
BAFF interacts with BAFFR to control the development and
survival of B2 cells and marginal zone B cells (Mackay and
Schneider, 2009). APRIL binds to TACI to accelerate CD40-inde-
pendent class switching (Mackay and Schneider, 2008), while
also promoting plasma cell survival through the BCMA receptor
(O’Connor et al., 2004). As members of the TNFR superfamily,
stimulation of BAFFR, TACI, and BCMA receptors triggers the
recruitment of TRAF adaptor proteins to activate NF-kB path-
ways, which are critical for B cell survival. Signaling through
BAFFR preferentially activates the alternative NF-kB2 pathway,
whereas TACI is a potent stimulator of the classical NF-kB1
pathway. BCR signaling is required to provide substrates for
sustaining the NF-kB2 pathway triggered by BAFF. In addition,
BAFFR signals can activate the PI3K-AKT1-mTOR pathway to
promote cellular metabolism (Mackay and Schneider, 2009). In
addition, TACI triggers class switching through direct associ-
ating with the adaptor MyD88 (He et al., 2010). Similar to T
lymphocytes, B cells express several coinhibitory receptors.
PD-1, now known as a key T cell checkpoint modulator, was
originally thought of as a coinhibitor for B cells (Okazaki et al.,
2001). Ligation of the PD-1 intracellular domain recruits the
phosphatase SHP-2, leading to the inhibition of BCR signaling
by dephosphorylating several key signal transducers in vitro
(Okazaki et al., 2001). Several recent studies support PD-1 as
a regulator for GC B cell survival and formation of memory
plasma cells because PD-1 deficiency or deficiency of its ligand
B7-H1 and B7-DC results in impaired memory B cell pools, likely
mediated by poor survival of follicular helper T cells (Good-Ja-
cobson et al., 2010). Similarly BTLA, another T cell coinhibitor,
attenuates BCR signaling by recruiting SHP-1 (Vendel et al.,
2009).
Natural Killer Cells
Natural killer (NK) cells are cytotoxic lymphocytes that mediate
innate immunity against viral infection and tumors. Amajor differ-
ence of NK cells from other lymphocyte lineages is that they
often utilize multiple activating receptors to transmit primary
signals, leading to rapid activation of NK cells (Moretta et al.,
2001). This is understandable in the context of NK cell functions
as the host’s rapid reacting force to survey the tissues for abnor-
mality. Functions of these germline-encoded receptors,
however, are still tightly regulated by a great number of cell
surface cosignaling molecules. The activation of NK cells can
result in direct cytotoxic attack on their targets and/or secretion
of array of cytokines and chemokines, which contributes to initi-
ation of antigen-specific responses. NK cells are also armedwith
a large number of coinhibitory molecules that control their
activity.
NK cell use multiple surface receptors to distinguish normal
healthy cells with abnormal cells undergoing various forms of
stress, such as viral infection or tumor transformation. Some
receptors detect viral proteins on the surface of infected cells,
which are structurally similar to MHC and otherwise intend to
evade immune recognition (Natarajan et al., 2002). Some recep-
tors can identify a type of stress molecule expressed on the
surface of viral-infected or malignant-transformed cells. Thosestress molecules are encoded by the host’s genome, yet are
rarely expressed by normal cells but upregulated by stressed
or diseased cells. For example, NKG2D identifies a series of
MHC-like ligands preferentially present on many tumor cells
(Raulet, 2003). In addition to its ability to bind to cytomegalovirus
(CMV) pp65, NKp30 has recently been shown to be a receptor for
B7-H6, a protein not found on normal cells but highly expressed
on varieties types of tumor cell lines (Brandt et al., 2009). These
activating NK cell receptors often have short intracellular
domains that lack intrinsic signaling activity. Their charged trans-
membrane regions, however, can associate with transmem-
brane adaptor molecules to transmit signals. For instance,
NKp44 couples to DAP12 while NKG2D uses the adaptor protein
DAP10 (Moretta et al., 2001). CD16, NKp30, and NKp46 recep-
tors associate with Fc3RIg and CD3x (Vivier et al., 2004).
Since NK cells share a common progenitor with T cells and in
many aspects are very closely related to T cells, it is not
surprising that a lot of surface molecules are shared between
NK cells and T cells. Many cosignaling molecules for T cells,
like CD137 (Wilcox et al., 2002), CD27 (Takeda et al., 2000),
CD96 (Fuchs et al., 2004), DNAM-1 (CD226) (Tahara-Hanaoka
et al., 2004), and LAIR-1 (Meyaard et al., 1997), are also found
to be crucial for NK cell activation, though their exact roles in
two cell types might not be identical. Signaling lymphocytic acti-
vation molecule (SLAM)-related and PVR-like proteins are two
main families that are important for the regulation of NK cell
function. SLAM family proteins have been shown to exhibit
homotypic interactions with the exception of 2B4, which recog-
nizes CD48. Interestingly, 2B4 can act as both a costimulatory
receptor and coinhibitory receptor for NK cells depending on
the signaling pathways it initiates (Moretta et al., 2001). The posi-
tive role of 2B4 requires its association with SLAM-associated
protein (SAP), leading to activation of numerous intracellular
molecules, such as Vav-1, PLCg, and SHIP (Cannons et al.,
2011). In the absence of SAP, 2B4 may deliver a negative signal
to NK cells by recruitment of EAT-2 or Csk. CD96 (Tactile) and
DNAM-1 are two receptors for PVR-like family ligands and
promote adhesion to ligand-expressing targets and enhance
the cytolytic capability of NK cells (Xu and Jin, 2010). In contrast,
engagement of TIGIT on NK cells by PVR leads to an ITIM-medi-
ated suppression (Stanietsky et al., 2009). One common feature
for NK cell coinhibitory receptors is that they contain an intracel-
lular ITIMmotif. Many coinhibitory receptors for NK cells, such as
CD94-NKG2A, KIR2DL1-3, and KIR3DL1-2, recognize MHC
molecules, which allow normal cells to avoid NK cell killing
(Lanier, 2005). Other important coinhibitory pathways include
LAIR-1-collagen, NKR-P1A-CLEC2D, KLRG1-cadherins (Vivier
et al., 2011), and ITIM-containing SIGLEC family members
(SIGLEC3, SIGLEC7, and SIGLEC9), which recognize sialic
acid-containing molecules (Avril et al., 2004; Herna´ndez-Case-
lles et al., 2006).
Myeloid-Derived Phagocytes
Monocytes and macrophages and dendritic cells represent two
subgroups of the mononuclear phagocyte system originally
described as a population of bone marrow-derived myeloid cells
(van Furth and Cohn, 1968). Monocytes are those circulating in
the bloodwhilemacrophages reside in tissues in the steady state
as well as during inflammation. Monocytes and macrophages
are critical effectors and regulators of inflammation (Dale et al.,Immunity 34, April 22, 2011 ª2011 Elsevier Inc. 473
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ogen-specific adaptive immunity and are central to the develop-
ment of adaptive immune response (Mellman and Steinman,
2001). A series of pattern recognition receptors (PRRs) are
utilized to receive primary signal to execute their distinctive func-
tions, including inflammation, opsonization, activation of
complement and coagulation cascades, and phagocytosis
(Janeway and Medzhitov, 2002). These PRRs can be expressed
on the cell surface, expressed in intracellular compartments, or
secreted into the bloodstream. Several classes of PRRs involved
in different aspects of immune functions for those myeloid cells
have been illustrated recently (Palm and Medzhitov, 2009).
Here we will focus on the inflammatory response as an example
to discuss the decision-making process for these myeloid
cells—that is, how inflammation is regulated by cosignals.
Pathogen infection is the most common way of triggering an
inflammatory response, as phagocytes express PRRs to recog-
nizemolecularmotifs conservedwithin aclassofmicrobes,which
are often named as pathogen-associated molecular patterns
(PAMPs) (Janeway, 1989). These receptors can be considered
to transduce a primary signal. Recent studies indicate that
PRRs are also responsible for recognizing endogenous
molecules released fromdamagedcells, termeddamage-associ-
ated molecular patterns (DAMPs) (Seong and Matzinger, 2004).
Currently, at least three typesofPRR families havebeen identified
(Takeuchi and Akira, 2010). These families include the Toll-like
receptors (TLRs), the Retinoic acid-inducible gene (RIG)-I-like
receptors (RLRs), and NOD-like receptors (NLRs). TLRs,
including ten functional members in human, are the first and
best characterized PRR family that sense invading pathogens
outside of the cell as well as in intracellular endosomes and lyso-
somes. Both RLRs and NLRs families are cytoplasmic proteins,
with RLRs recognizing short double-stranded RNA derived from
viruses while NLRs sensing DAMPs caused by tissue injury
(Bowie and Unterholzner, 2008; Philpott and Girardin, 2010).
The activation of these PRRs involves distinctive signaling
cascades, leading to the secretion of different patterns of pro-
inflammatory cytokines. TLR activation leads to the direct inter-
actions of the Toll-IL-1 receptor (TIR) domain with a cytoplasmic
TIR-containing adaptive molecule, such as MyD88 or TRIF
(Takeda and Akira, 2004). Activation of the MyD88-dependent
signaling pathway results in the activation of the classic NF-kB
pathway, which leads to the expression of numerous proinflam-
matory cytokines, such as IL-6, IL-12, and TNF-a. TRIF is
required for the MyD88-independent pathway in TLR3- and
TLR4-mediated responses. The recruitment of TRIF leads to
the activation of transcription factor IRF-3, thereby inducing
type I interferon (IFN) secretion. The RLR family has at least three
members: RIG-I, MDA5, and LGP2 (Nakhaei et al., 2009). They
are composed of two N-terminal caspase recruitment domains
(CARDs), a central DEAD box helicase domain, and a C-terminal
regulatory domain. RLRs recognize dsRNA from RNA viruses in
cytoplasm. Activation of RIG-I and MDA5 leads to its homophilic
interaction with IPS-1 through CARD domains, turning on
signaling cascades resulting into the expression of type I IFN
genes. The NLR family contains more than twenty members in
human and their domain architecture consists of a variable
N-terminal effector domain, a central nucleotide-binding domain
(NBD) and C-terminal leucine-rich repeats (LRRs) (Philpott and474 Immunity 34, April 22, 2011 ª2011 Elsevier Inc.Girardin, 2010). NOD2 senses bacterial infection and interacts
with the receptor-interacting serine-threonine protein kinase 2
(RIPK2) to activate NF-kB and MAPK, therefore promoting the
expression of proinflammatory molecules (Strober et al., 2006).
The NLR family members NLRP1, NLRP3, and NLRC4 assemble
large protein complexes known as inflammasomes, which
respond to DAMPs and are responsible for the activation of cas-
pase-1 and hence the production of IL-1b and IL-18 (Philpott and
Girardin, 2010).
Unlike T cells, the innate immune response mediated by DCs,
monocytes, and macrophages is a rapid process and does not
require any antigen processing. Yet unrestrained signaling by
PRRs in DCs andmacrophageswould generate a chronic inflam-
matorymilieu or cytokine storm that can lead to sepsis. As for any
dynamic system, the innate immune response must be carefully
regulated so that turning it onmust be followedwith amechanism
that can turn it off. In fact, many coreceptors on these myeloid
cells function as pivotal regulators that can either positively or
negatively control inflammation, which here we call as cosignals.
Similar to T cell cosignals, cosignalingmolecules forDCs,macro-
phages, and monocytes belong to many molecular families, and
many of them have preferential roles on these cell types. For
example, CD200R, a member of the Ig superfamily, is a coinhibi-
tory receptormainly on tissuemacrophages (Hoek et al., 2000). In
contrast, DC-SIGN is a C-type lectin molecule preferentially
found on DCs (Geijtenbeek et al., 2000).
Each cosignal utilizes different intracellular machinery to
modulate TLR signaling. Many members of the triggering
receptor expressed on myeloid cells (TREM) family modulate
myeloid cell function through their association with DAP12
(Ford and McVicar, 2009). Another costimulatory pathway for
myeloid cells is the plexin-A4-Sema3A pair (Wen et al., 2010).
Plexin-A4 genetically targeted mice are highly resistant to septic
shock induced by TLR agonists, and its ligand, Sema3A,
promotes LPS-induced cytokine production through plexin-A4.
Signaling studies indicate that Plexin-A4 is required for TLR-
induced activation of Ras-related C3 botulinum toxin substrate
1(Rac1), c-Jun N-terminal kinase (JNK), and NF-kB. In contrast,
Sema6D-plexin-A1, another pair belonging to the plexin-sema-
phorin family, induces DCs maturation through a different
pathway (Takegahara et al., 2006). Sema6D promotes the asso-
ciation between plexin-A1 and Trem-2, therefore recruiting
adaptor DAP12 to activate downstream signaling.
One common pathway for coinhibitory molecules to dampen
TLR-mediated inflammatory pathways inmyeloid cells is through
the ITIM motif within the cytoplasmic domain that is used to
recruit and interact with the phosphatases SHP-1 and SHP-2.
Those proteins are mainly Ig superfamily members, including
inhibitory members of Ig-like transcripts (ILTs), CD300 family
(Clark et al., 2009), and TREM-like transcript-1 (TLT-1) (Ford
and McVicar, 2009). CD200R does not have an ITIM but instead
contains an NPxY motif in its cytoplasmic domain to recruit
inhibitory adaptor proteins Dok1 and Dok2 (Minas and Liver-
sidge, 2006). Another good example of coinhibitory molecules
for DCs is DC-SIGN, which recognizes the carbohydrate motifs
on its ligands to tailor TLR signaling on DCs. DC-SIGN engage-
ment modifies TLR signaling by activating the serine-threonine
kinase Raf-1, leading to acetylation of the p65 subunit of
NF-kB (Gringhuis et al., 2007).
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The mast cell is a major cell type playing a key role in allergic
inflammatory responses. Mast cells bind to aggregated IgE
induced by allergen and rapidly release numerous proinflamma-
tory mediators, a process referred as degranulation. In the past
decade mast cells have been recognized as immune cells that
not only act as key effector cells in allergic responses, but also
execute regulatory functions in innate as well as adaptive
immune responses (Sayed et al., 2008).
The primary signal to initiatemast cell activation is triggered by
allergen-induced aggregation of high-affinity receptors for IgE
(Fc3RIs) (Sayed et al., 2008). The Fc3RI receptor is a tetrameric
complex that comprises an a chain, which is responsible for
IgE binding, a b-chain, and a disulphide-linked g-chain homo-
dimer, which are responsible for signaling. Following Fc3RI
aggregation, the protein tyrosine kinases FYN and Syk become
activated, which results in tyrosine phosphorylation of the
adaptor molecule GAB2 and subsequently the activation of
phosphatidylinositol 3-kinase (PI3K) and PLCg (Sayed et al.,
2008). The transmembrane adaptor molecules LAT and NTAL
are crucial for coordination of the downstream signaling path-
ways that are required for the release of the various proinflamma-
tory mediators.
CD28, DNAM-1, and CD137 are T cell costimulatory receptors
known to regulate mast cell function as well (Sayed et al., 2008).
SCF-KIT is the most well-studied costimulatory pathway for
mast cells (Sayed et al., 2008). SCF alone does not induce
mast cell degranulation while simultaneous addition of SCF
and antigen markedly increases the secretion of multiple cyto-
kines in both human andmousemast cells. SCF signaling results
in the activation numerous signaling pathways, including the
activation of PI3K, PLCg, calcium mobilization, and MAPK-
cascade, which are also triggered by Fc3RI stimulation.
However, SCF stimulation fails to induce tyrosine phosphoryla-
tion or to activate PKC, which might explain its inability to
stimulate mast cell degranulation by itself (Sayed et al., 2008).
The coinhibitory receptors for mast cell include PIR-B (Uehara
et al., 2001), CD300a (Bachelet et al., 2005), gp49B1 (Sayed
et al., 2008), and allergin-1 (Hitomi et al., 2010), which all contain
ITIMs within their cytoplasmic domains. During the initiation of
mast cell activation, the phosphorylation of ITIMs recruits the
tyrosine phosphatases SHP-1 and SHP-2 to block early signals
mediated by Fc3RI cross-linking. However, ligands for many of
these receptors are yet to be identified.
Perspectives
Cell-cell communication is a crucial mode formulticellular organ-
isms to accomplish complex biological functions and various
signalingmolecules have evolved tomeet complicated demands
to connect extracellular stimuli with intracellular components.
Our tide model incorporates the majority, if not all, of immune
cells in the context of an initiator and modulator concept to
describe the rise of immune response to environmental stimuli
due to transmission of primary and costimulatory signals while
this response subsequently falls owing to the presence of coin-
hibitory signals. This process is reminiscent of the rise and fall
of sea levels due to gravity forces by the sun, the moon, and
the Earth’s rotation. In addition to adaptive immunity, our model
might better describe how innate cells trigger an inflammatoryresponse and how these responses are regulated. Cosignaling
molecules, whose expression is responsive to local environ-
ments, balance the communication between host innate cells
and microorganisms. The intimate interaction between microor-
ganisms and the host immune system covers a wide range of
contacts, which are far beyond those between DAMPs and
PRRs. Compared with infectious pathogens, commensal
bacteria preferentially trigger inhibitory cosignals or fail to induce
stimulatory cosignals directly or indirectly to host immune cells. It
remains to be seen how each cosignal is induced or dampened
to cooperate with PRRs, and in so doing combat infectious path-
ogens, or induce tolerance to commensal bacteria.
The same cosignaling molecule could be found on various
immune cell types and execute the same or similar functions,
dependent on receptor(s) or ligand(s) with which it could interact.
This would allow maximal efficiency of immune responses to be
initiated and expanded, leading to a highly coordinated response
of multiple cell types. In this context, tight control from coinhibi-
tion becomes critical to tune down such responses in a certain
level to prevent tissue or organ damage spanning from an acute
inflammation to chronic autoimmunity.
It appears also important that one cell type possessesmultiple
cosignaling molecules. Cosignaling molecules for certain cell
types usually come from one or two protein families and execute
overlapping but not redundant roles. This cosignal mode could
ensure that dysfunction of one cosignal could be offset by other
cosignals, so that one cosignal defect would not lead to extreme
immune dysfunction. At the same time, each cosignal with similar
function could specialize in a certain step or type of immune
response, thereby exploiting its unique expression profile, in
terms of expression location, timing, and sensitivity to induction.
On the other hand, the types of coreceptors are far broader than
weoriginally thought, andmanypathways fromunrelated families
could have similar regulatory function but use distinct signaling
machineries. In thatway, thesecosignals couldoperate inparallel
without any signalingdisruptionor conflict. Finally, themultiplicity
of cosignals ensures that one pathogen cannot elude immune
response simply by targeting one pathway.
ACKNOWLEDGMENTS
We thank B. Cadugan for editing the manuscript. The study has been partially
supported by National Institutes of Health grants CA98731, CA106861,
CA142779, AI72592, CA97085, and CA85721 and the Melanoma Research
Alliance.
REFERENCES
Alvarez, I.B., Pasquinelli, V., Jurado, J.O., Abbate, E., Musella, R.M., de la
Barrera, S.S., and Garcı´a, V.E. (2010). Role played by the programmed
death-1-programmed death ligand pathway during innate immunity against
Mycobacterium tuberculosis. J. Infect. Dis. 202, 524–532.
Avril, T., Floyd, H., Lopez, F., Vivier, E., and Crocker, P.R. (2004). The
membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical
for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs
expressed on human monocytes and NK cells. J. Immunol. 173, 6841–6849.
Bachelet, I., Munitz, A., Moretta, A., Moretta, L., and Levi-Schaffer, F. (2005).
The inhibitory receptor IRp60 (CD300a) is expressed and functional on human
mast cells. J. Immunol. 175, 7989–7995.
Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H.,
Freeman, G.J., and Ahmed, R. (2006). Restoring function in exhausted CD8
T cells during chronic viral infection. Nature 439, 682–687.Immunity 34, April 22, 2011 ª2011 Elsevier Inc. 475
Immunity
ReviewBas, A., Swamy, M., Abeler-Do¨rner, L., Williams, G., Pang, D.J., Barbee, S.D.,
and Hayday, A.C. (2011). Butyrophilin-like 1 encodes an enterocyte protein
that selectively regulates functional interactions with T lymphocytes. Proc.
Natl. Acad. Sci. USA 108, 4376–4381.
Bonneville, M., O’Brien, R.L., and Born, W.K. (2010). Gammadelta T cell
effector functions: a blend of innate programming and acquired plasticity.
Nat. Rev. Immunol. 10, 467–478.
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B.,
Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., et al. (2003). Identification
of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human
DNAM-1 (CD226) activating molecule. J. Exp. Med. 198, 557–567.
Bowie, A.G., and Unterholzner, L. (2008). Viral evasion and subversion of
pattern-recognition receptor signalling. Nat. Rev. Immunol. 8, 911–922.
Brandt, C.S., Baratin, M., Yi, E.C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B.,
Ostrander, C.D., Kaifu, T., Chabannon, C., et al. (2009). The B7 family member
B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30
in humans. J. Exp. Med. 206, 1495–1503.
Bretscher, P., and Cohn, M. (1970). A theory of self-nonself discrimination.
Science 169, 1042–1049.
Brown, D., Trowsdale, J., and Allen, R. (2004). The LILR family: modulators of
innate and adaptive immune pathways in health and disease. Tissue Antigens
64, 215–225.
Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., and Freeman, G.J.
(2007). Programmed death-1 ligand 1 interacts specifically with the B7-1 cos-
timulatory molecule to inhibit T cell responses. Immunity 27, 111–122.
Cai, G., Anumanthan, A., Brown, J.A., Greenfield, E.A., Zhu, B., and Freeman,
G.J. (2008). CD160 inhibits activation of human CD4+ T cells through interac-
tion with herpesvirus entry mediator. Nat. Immunol. 9, 176–185.
Cannons, J.L., Tangye, S.G., and Schwartzberg, P.L. (2011). SLAM Family
Receptors and SAP Adaptors in Immunity. Annu. Rev. Immunol. 29, 665–705.
Chapoval, A.I., Ni, J., Lau, J.S., Wilcox, R.A., Flies, D.B., Liu, D., Dong, H., Sica,
G.L., Zhu, G., Tamada, K., and Chen, L. (2001). B7-H3: a costimulatory mole-
cule for T cell activation and IFN-gamma production. Nat. Immunol. 2,
269–274.
Chen, L. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of
T-cell immunity. Nat. Rev. Immunol. 4, 336–347.
Chen, T.T., Li, L., Chung, D.H., Allen, C.D., Torti, S.V., Torti, F.M., Cyster, J.G.,
Chen, C.Y., Brodsky, F.M., Niemi, E.C., et al. (2005). TIM-2 is expressed on B
cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J. Exp.
Med. 202, 955–965.
Clark, G.J., Ju, X., Azlan, M., Tate, C., Ding, Y., and Hart, D.N. (2009). The
CD300 molecules regulate monocyte and dendritic cell functions. Immunobi-
ology 214, 730–736.
Croft, M. (2009). The role of TNF superfamily members in T-cell function and
diseases. Nat. Rev. Immunol. 9, 271–285.
Dale, D.C., Boxer, L., and Liles, W.C. (2008). The phagocytes: neutrophils and
monocytes. Blood 112, 935–945.
Duhen, T., Pasero, C., Mallet, F., Barbarat, B., Olive, D., and Costello, R.T.
(2004). LIGHT costimulates CD40 triggering and induces immunoglobulin
secretion; a novel key partner in T cell-dependent B cell terminal differentia-
tion. Eur. J. Immunol. 34, 3534–3541.
Egen, J.G., and Allison, J.P. (2002). Cytotoxic T lymphocyte antigen-4 accu-
mulation in the immunological synapse is regulated by TCR signal strength.
Immunity 16, 23–35.
Fife, B.T., Pauken, K.E., Eagar, T.N., Obu, T., Wu, J., Tang, Q., Azuma, M.,
Krummel, M.F., and Bluestone, J.A. (2009). Interactions between PD-1 and
PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Im-
munol. 10, 1185–1192.
Ford, J.W., and McVicar, D.W. (2009). TREM and TREM-like receptors in
inflammation and disease. Curr. Opin. Immunol. 21, 38–46.
Fuchs, A., Cella, M., Giurisato, E., Shaw, A.S., and Colonna, M. (2004). Cutting
edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with
the poliovirus receptor (CD155). J. Immunol. 172, 3994–3998.476 Immunity 34, April 22, 2011 ª2011 Elsevier Inc.Geijtenbeek, T.B., Kwon, D.S., Torensma, R., van Vliet, S.J., van Duijnhoven,
G.C., Middel, J., Cornelissen, I.L., Nottet, H.S., KewalRamani, V.N., Littman,
D.R., et al. (2000). DC-SIGN, a dendritic cell-specific HIV-1-binding protein
that enhances trans-infection of T cells. Cell 100, 587–597.
Good-Jacobson, K.L., Szumilas, C.G., Chen, L., Sharpe, A.H., Tomayko,
M.M., and Shlomchik, M.J. (2010). PD-1 regulates germinal center B cell
survival and the formation and affinity of long-lived plasma cells. Nat. Immunol.
11, 535–542.
Greenwald, R.J., Freeman, G.J., and Sharpe, A.H. (2005). The B7 family revis-
ited. Annu. Rev. Immunol. 23, 515–548.
Grewal, I.S., and Flavell, R.A. (1998). CD40 and CD154 in cell-mediated immu-
nity. Annu. Rev. Immunol. 16, 111–135.
Gringhuis, S.I., den Dunnen, J., Litjens, M., van Het Hof, B., van Kooyk, Y., and
Geijtenbeek, T.B. (2007). C-type lectin DC-SIGN modulates Toll-like receptor
signaling via Raf-1 kinase-dependent acetylation of transcription factor
NF-kappaB. Immunity 26, 605–616.
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A.,
Candeloro, P., Belladonna, M.L., Bianchi, R., Fioretti, M.C., and Puccetti, P.
(2002). CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3,
1097–1101.
Hashiguchi, M., Kobori, H., Ritprajak, P., Kamimura, Y., Kozono, H., and
Azuma, M. (2008). Triggering receptor expressed on myeloid cell-like tran-
script 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell
responses. Proc. Natl. Acad. Sci. USA 105, 10495–10500.
He, B., Santamaria, R., Xu,W., Cols, M., Chen, K., Puga, I., Shan,M., Xiong, H.,
Bussel, J.B., Chiu, A., et al. (2010). The transmembrane activator TACI triggers
immunoglobulin class switching by activating B cells through the adaptor
MyD88. Nat. Immunol. 11, 836–845.
Herna´ndez-Caselles, T., Martı´nez-Esparza, M., Pe´rez-Oliva, A.B., Quintanilla-
Cecconi, A.M., Garcı´a-Alonso, A., Alvarez-Lo´pez, D.M., and Garcı´a-Pen˜arru-
bia, P. (2006). A study of CD33 (SIGLEC-3) antigen expression and function
on activated human T and NK cells: two isoforms of CD33 are generated by
alternative splicing. J. Leukoc. Biol. 79, 46–58.
Hitomi, K., Tahara-Hanaoka, S., Someya, S., Fujiki, A., Tada, H., Sugiyama, T.,
Shibayama, S., Shibuya, K., and Shibuya, A. (2010). An immunoglobulin-like
receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hyper-
sensitivity reactions. Nat. Immunol. 11, 601–607.
Hoek, R.M., Ruuls, S.R., Murphy, C.A., Wright, G.J., Goddard, R., Zurawski,
S.M., Blom, B., Homola, M.E., Streit, W.J., Brown, M.H., et al. (2000). Down-
regulation of the macrophage lineage through interaction with OX2 (CD200).
Science 290, 1768–1771.
Huard, B., Tournier, M., Hercend, T., Triebel, F., and Faure, F. (1994). Lympho-
cyte-activation gene 3/major histocompatibility complex class II interaction
modulates the antigenic response of CD4+ T lymphocytes. Eur. J. Immunol.
24, 3216–3221.
Huppa, J.B., and Davis, M.M. (2003). T-cell-antigen recognition and the immu-
nological synapse. Nat. Rev. Immunol. 3, 973–983.
Janeway, C.A., Jr. (1989). Approaching the asymptote? Evolution and revolu-
tion in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1–13.
Janeway, C.A., Jr., and Medzhitov, R. (2002). Innate immune recognition.
Annu. Rev. Immunol. 20, 197–216.
Kawasaki, N., Rademacher, C., and Paulson, J.C. (2010). CD22 regulates
adaptive and innate immune responses of B cells. J. Innate Immun., in press.
Published online December 17, 2010. 10.1159/000322375.
Kikuchi, T., Worgall, S., Singh, R., Moore, M.A., and Crystal, R.G. (2000).
Dendritic cells genetically modified to express CD40 ligand and pulsed with
antigen can initiate antigen-specific humoral immunity independent of CD4+
T cells. Nat. Med. 6, 1154–1159.
Kobata, T., Jacquot, S., Kozlowski, S., Agematsu, K., Schlossman, S.F., and
Morimoto, C. (1995). CD27-CD70 interactions regulate B-cell activation by
T cells. Proc. Natl. Acad. Sci. USA 92, 11249–11253.
Kumanogoh, A., Watanabe, C., Lee, I., Wang, X., Shi, W., Araki, H., Hirata, H.,
Iwahori, K., Uchida, J., Yasui, T., et al. (2000). Identification of CD72 as
a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism
for regulating B cell signaling. Immunity 13, 621–631.
Immunity
ReviewKumanogoh, A., Marukawa, S., Suzuki, K., Takegahara, N., Watanabe, C.,
Ch’ng, E., Ishida, I., Fujimura, H., Sakoda, S., Yoshida, K., and Kikutani, H.
(2002). Class IV semaphorin Sema4A enhances T-cell activation and interacts
with Tim-2. Nature 419, 629–633.
Kurosaki, T., Shinohara, H., and Baba, Y. (2010). B cell signaling and fate deci-
sion. Annu. Rev. Immunol. 28, 21–55.
Lafferty, K.J., and Cunningham, A.J. (1975). A new analysis of allogeneic inter-
actions. Aust. J. Exp. Biol. Med. Sci. 53, 27–42.
Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J.,
Devon, K., Dewar, K., Doyle, M., FitzHugh, W., et al; International Human
Genome Sequencing Consortium. (2001). Initial sequencing and analysis of
the human genome. Nature 409, 860–921.
Lanier, L.L. (2005). NK cell recognition. Annu. Rev. Immunol. 23, 225–274.
Lebbink, R.J., de Ruiter, T., Adelmeijer, J., Brenkman, A.B., van Helvoort, J.M.,
Koch, M., Farndale, R.W., Lisman, T., Sonnenberg, A., Lenting, P.J., and
Meyaard, L. (2006). Collagens are functional, high affinity ligands for the inhib-
itory immune receptor LAIR-1. J. Exp. Med. 203, 1419–1425.
Leitner, J., Klauser, C., Pickl, W.F., Sto¨ckl, J., Majdic, O., Bardet, A.F., Kreil,
D.P., Dong, C., Yamazaki, T., Zlabinger, G., et al. (2009). B7-H3 is a potent
inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 inter-
action. Eur. J. Immunol. 39, 1754–1764.
Linsley, P.S., Clark, E.A., and Ledbetter, J.A. (1990). T-cell antigen CD28medi-
ates adhesion with B cells by interacting with activation antigen B7/BB-1.
Proc. Natl. Acad. Sci. USA 87, 5031–5035.
Mackay, F., and Schneider, P. (2008). TACI, an enigmatic BAFF/APRIL
receptor, with new unappreciated biochemical and biological properties.
Cytokine Growth Factor Rev. 19, 263–276.
Mackay, F., and Schneider, P. (2009). Cracking the BAFF code. Nat. Rev. Im-
munol. 9, 491–502.
Mauri, D.N., Ebner, R., Montgomery, R.I., Kochel, K.D., Cheung, T.C., Yu, G.L.,
Ruben, S., Murphy, M., Eisenberg, R.J., Cohen, G.H., et al. (1998). LIGHT,
a new member of the TNF superfamily, and lymphotoxin alpha are ligands
for herpesvirus entry mediator. Immunity 8, 21–30.
McHeyzer-Williams, L.J., and McHeyzer-Williams, M.G. (2005). Antigen-
specific memory B cell development. Annu. Rev. Immunol. 23, 487–513.
Mellman, I., and Steinman, R.M. (2001). Dendritic cells: specialized and regu-
lated antigen processing machines. Cell 106, 255–258.
Meyaard, L., Adema, G.J., Chang, C., Woollatt, E., Sutherland, G.R., Lanier,
L.L., and Phillips, J.H. (1997). LAIR-1, a novel inhibitory receptor expressed
on human mononuclear leukocytes. Immunity 7, 283–290.
Meyers, J.H., Chakravarti, S., Schlesinger, D., Illes, Z., Waldner, H., Umetsu,
S.E., Kenny, J., Zheng, X.X., Umetsu, D.T., DeKruyff, R.H., et al. (2005). TIM-
4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell prolif-
eration. Nat. Immunol. 6, 455–464.
Migone, T.S., Zhang, J., Luo, X., Zhuang, L., Chen, C., Hu, B., Hong, J.S.,
Perry, J.W., Chen, S.F., Zhou, J.X., et al. (2002). TL1A is a TNF-like ligand
for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16,
479–492.
Minas, K., and Liversidge, J. (2006). Is the CD200/CD200 receptor interaction
more than just a myeloid cell inhibitory signal? Crit. Rev. Immunol. 26,
213–230.
Miyanishi, M., Tada, K., Koike, M., Uchiyama, Y., Kitamura, T., and Nagata, S.
(2007). Identification of Tim4 as a phosphatidylserine receptor. Nature 450,
435–439.
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M.C., Bias-
soni, R., and Moretta, L. (2001). Activating receptors and coreceptors involved
in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19,
197–223.
Mueller, D.L., Jenkins, M.K., and Schwartz, R.H. (1989). Clonal expansion
versus functional clonal inactivation: a costimulatory signalling pathway deter-
mines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol.
7, 445–480.Murphy, K.M., Nelson, C.A., and Sedy´, J.R. (2006). Balancing co-stimulation
and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 6, 671–681.
Nakayama, M., Akiba, H., Takeda, K., Kojima, Y., Hashiguchi, M., Azuma, M.,
Yagita, H., and Okumura, K. (2009). Tim-3 mediates phagocytosis of apoptotic
cells and cross-presentation. Blood 113, 3821–3830.
Nakhaei, P., Genin, P., Civas, A., and Hiscott, J. (2009). RIG-I-like receptors:
sensing and responding to RNA virus infection. Semin. Immunol. 21, 215–222.
Natarajan, K., Dimasi, N.,Wang, J., Mariuzza, R.A., andMargulies, D.H. (2002).
Structure and function of natural killer cell receptors: multiple molecular solu-
tions to self, nonself discrimination. Annu. Rev. Immunol. 20, 853–885.
Nguyen, T., Liu, X.K., Zhang, Y., and Dong, C. (2006). BTNL2, a butyrophilin-
like molecule that functions to inhibit T cell activation. J. Immunol. 176,
7354–7360.
O’Connor, B.P., Raman, V.S., Erickson, L.D., Cook, W.J., Weaver, L.K., Aho-
nen, C., Lin, L.L., Mantchev, G.T., Bram, R.J., and Noelle, R.J. (2004). BCMA is
essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med.
199, 91–98.
O’Neill, L.A. (2007). TAMpering with toll-like receptor signaling. Cell 131, 1039–
1041.
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., and Honjo, T. (2001). PD-1
immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src
homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.
Proc. Natl. Acad. Sci. USA 98, 13866–13871.
Okazaki, T., Okazaki, I.M., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato,
Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011). PD-1 and LAG-3 inhib-
itory co-receptors act synergistically to prevent autoimmunity in mice. J. Exp.
Med. 208, 395–407.
Orabona, C., Grohmann, U., Belladonna, M.L., Fallarino, F., Vacca, C.,
Bianchi, R., Bozza, S., Volpi, C., Salomon, B.L., Fioretti, M.C., et al. (2004).
CD28 induces immunostimulatory signals in dendritic cells via CD80 and
CD86. Nat. Immunol. 5, 1134–1142.
Palm, N.W., and Medzhitov, R. (2009). Pattern recognition receptors and
control of adaptive immunity. Immunol. Rev. 227, 221–233.
Park, J.J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine,
M.M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010). B7-H1/
CD80 interaction is required for the induction and maintenance of peripheral
T-cell tolerance. Blood 116, 1291–1298.
Philpott, D.J., and Girardin, S.E. (2010). Nod-like receptors: sentinels at host
membranes. Curr. Opin. Immunol. 22, 428–434.
Raulet, D.H. (2003). Roles of the NKG2D immunoreceptor and its ligands. Nat.
Rev. Immunol. 3, 781–790.
Rudd, C.E., and Schneider, H. (2003). Unifying concepts in CD28, ICOS and
CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3, 544–556.
Said, E.A., Dupuy, F.P., Trautmann, L., Zhang, Y., Shi, Y., El-Far, M., Hill, B.J.,
Noto, A., Ancuta, P., Peretz, Y., et al. (2010). Programmed death-1-induced
interleukin-10 production by monocytes impairs CD4+ T cell activation during
HIV infection. Nat. Med. 16, 452–459.
Sayed, B.A., Christy, A., Quirion, M.R., and Brown, M.A. (2008). The master
switch: the role of mast cells in autoimmunity and tolerance. Annu. Rev. Immu-
nol. 26, 705–739.
Schneider, H., Downey, J., Smith, A., Zinselmeyer, B.H., Rush, C., Brewer,
J.M., Wei, B., Hogg, N., Garside, P., and Rudd, C.E. (2006). Reversal of the
TCR stop signal by CTLA-4. Science 313, 1972–1975.
Seong, S.Y., and Matzinger, P. (2004). Hydrophobicity: an ancient damage-
associated molecular pattern that initiates innate immune responses. Nat.
Rev. Immunol. 4, 469–478.
Sharpe, A.H. (2009). Mechanisms of costimulation. Immunol. Rev. 229, 5–11.
Sica, G.L., Choi, I.H., Zhu, G., Tamada, K., Wang, S.D., Tamura, H., Chapoval,
A.I., Flies, D.B., Bajorath, J., and Chen, L. (2003). B7-H4, a molecule of the B7
family, negatively regulates T cell immunity. Immunity 18, 849–861.
Smith, I.A., Knezevic, B.R., Ammann, J.U., Rhodes, D.A., Aw, D., Palmer, D.B.,
Mather, I.H., and Trowsdale, J. (2010). BTN1A1, the mammary glandImmunity 34, April 22, 2011 ª2011 Elsevier Inc. 477
Immunity
Reviewbutyrophilin, and BTN2A2 are both inhibitors of T cell activation. J. Immunol.
184, 3514–3525.
Smith-Garvin, J.E., Koretzky, G.A., and Jordan, M.S. (2009). T cell activation.
Annu. Rev. Immunol. 27, 591–619.
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine,
Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009). The interaction of TIGIT
with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad.
Sci. USA 106, 17858–17863.
Stefferl, A., Schubart, A., Storch, M., 2, Amini, A., Mather, I., Lassmann, H., and
Linington, C. (2000). Butyrophilin, a milk protein, modulates the encephalito-
genic T cell response to myelin oligodendrocyte glycoprotein in experimental
autoimmune encephalomyelitis. J. Immunol. 165, 2859–2865.
Strober, W., Murray, P.J., Kitani, A., and Watanabe, T. (2006). Signalling path-
ways and molecular interactions of NOD1 and NOD2. Nat. Rev. Immunol. 6,
9–20.
Sugamura, K., Ishii, N., andWeinberg, A.D. (2004). Therapeutic targeting of the
effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 4, 420–431.
Tahara-Hanaoka, S., Shibuya, K., Onoda, Y., Zhang, H., Yamazaki, S.,
Miyamoto, A., Honda, S., Lanier, L.L., and Shibuya, A. (2004). Functional char-
acterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and
nectin-2 (PRR-2/CD112). Int. Immunol. 16, 533–538.
Takeda, K., and Akira, S. (2004). TLR signaling pathways. Semin. Immunol. 16,
3–9.
Takeda, K., Oshima, H., Hayakawa, Y., Akiba, H., Atsuta, M., Kobata, T.,
Kobayashi, K., Ito, M., Yagita, H., and Okumura, K. (2000). CD27-mediated
activation of murine NK cells. J. Immunol. 164, 1741–1745.
Takegahara, N., Takamatsu, H., Toyofuku, T., Tsujimura, T., Okuno, T.,
Yukawa, K., Mizui, M., Yamamoto, M., Prasad, D.V., Suzuki, K., et al. (2006).
Plexin-A1 and its interaction with DAP12 in immune responses and bone
homeostasis. Nat. Cell Biol. 8, 615–622.
Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflam-
mation. Cell 140, 805–820.
Takeuchi, A., Itoh, Y., Takumi, A., Ishihara, C., Arase, N., Yokosuka, T., Koseki,
H., Yamasaki, S., Takai, Y., Miyoshi, J., et al. (2009). CRTAMconfers late-stage
activation of CD8+ T cells to regulate retention within lymph node. J. Immunol.
183, 4220–4228.
Tsushima, F., Yao, S., Shin, T., Flies, A., Flies, S., Xu, H., Tamada, K., Pardoll,
D.M., and Chen, L. (2007). Interaction between B7-H1 and PD-1 determines
initiation and reversal of T-cell anergy. Blood 110, 180–185.
Uehara, T., Ble´ry, M., Kang, D.W., Chen, C.C., Ho, L.H., Gartland, G.L., Liu,
F.T., Vivier, E., Cooper, M.D., and Kubagawa, H. (2001). Inhibition of IgE-medi-
ated mast cell activation by the paired Ig-like receptor PIR-B. J. Clin. Invest.
108, 1041–1050.
Vallabhapurapu, S., and Karin, M. (2009). Regulation and function of NF-kap-
paB transcription factors in the immune system. Annu. Rev. Immunol. 27,
693–733.
van den Heuvel, M.J., Garg, N., Van Kaer, L., and Haeryfar, S.M. (2011). NKT
cell costimulation: experimental progress and therapeutic promise. Trends
Mol. Med. 17, 65–77.
van Furth, R., and Cohn, Z.A. (1968). The origin and kinetics of mononuclear
phagocytes. J. Exp. Med. 128, 415–435.
Vendel, A.C., Calemine-Fenaux, J., Izrael-Tomasevic, A., Chauhan, V., Arnott,
D., and Eaton, D.L. (2009). B and T lymphocyte attenuator regulates B cell
receptor signaling by targeting Syk and BLNK. J. Immunol. 182, 1509–1517.
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G.,
Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A., et al. (2001). The sequence
of the human genome. Science 291, 1304–1351.
Verdino, P., Witherden, D.A., Havran, W.L., andWilson, I.A. (2010). Themolec-
ular interaction of CAR and JAML recruits the central cell signal transducer
PI3K. Science 329, 1210–1214.
Vinay, D.S., and Kwon, B.S. (2011). 4-1BB signaling beyond T cells. Cell. Mol.
Immunol., in press. Published online January 10, 2011. 10.1038/cmi.2010.82.478 Immunity 34, April 22, 2011 ª2011 Elsevier Inc.Vivier, E., Nune`s, J.A., and Ve´ly, F. (2004). Natural killer cell signaling pathways.
Science 306, 1517–1519.
Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L.,
Yokoyama, W.M., and Ugolini, S. (2011). Innate or adaptive immunity? The
example of natural killer cells. Science 331, 44–49.
Vogt, L., Schmitz, N., Kurrer, M.O., Bauer, M., Hinton, H.I., Behnke, S., Gatto,
D., Sebbel, P., Beerli, R.R., Sonderegger, I., et al. (2006). VSIG4, a B7 family-
related protein, is a negative regulator of T cell activation. J. Clin. Invest. 116,
2817–2826.
Wang, S., Bajorath, J., Flies, D.B., Dong, H., Honjo, T., and Chen, L. (2003).
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple
costimulatory function from PD-1 interaction. J. Exp. Med. 197, 1083–1091.
Watanabe, N., Gavrieli, M., Sedy, J.R., Yang, J., Fallarino, F., Loftin, S.K.,
Hurchla, M.A., Zimmerman, N., Sim, J., Zang, X., et al. (2003). BTLA is
a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Im-
munol. 4, 670–679.
Watts, T.H. (2005). TNF/TNFR family members in costimulation of T cell
responses. Annu. Rev. Immunol. 23, 23–68.
Wen, H., Lei, Y., Eun, S.Y., and Ting, J.P. (2010). Plexin-A4-semaphorin 3A
signaling is required for Toll-like receptor- and sepsis-induced cytokine storm.
J. Exp. Med. 207, 2943–2957.
Whang, M.I., Guerra, N., and Raulet, D.H. (2009). Costimulation of dendritic
epidermal gammadelta T cells by a new NKG2D ligand expressed specifically
in the skin. J. Immunol. 182, 4557–4564.
Wilcox, R.A., Tamada, K., Strome, S.E., and Chen, L. (2002). Signaling through
NK cell-associated CD137 promotes both helper function for CD8+ cytolytic
T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. 169,
4230–4236.
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z.,
Nomura, T., and Sakaguchi, S. (2008). CTLA-4 control over Foxp3+ regulatory
T cell function. Science 322, 271–275.
Witherden, D.A., Verdino, P., Rieder, S.E., Garijo, O., Mills, R.E., Teyton, L.,
Fischer, W.H., Wilson, I.A., and Havran, W.L. (2010). The junctional adhesion
molecule JAML is a costimulatory receptor for epithelial gammadelta T cell
activation. Science 329, 1205–1210.
Xu, Z., and Jin, B. (2010). A novel interface consisting of homologous immuno-
globulin superfamily members with multiple functions. Cell. Mol. Immunol. 7,
11–19.
Xu, Y., Flies, A.S., Flies, D.B., Zhu, G., Anand, S., Flies, S.J., Xu, H., Anders,
R.A., Hancock, W.W., Chen, L., and Tamada, K. (2007). Selective targeting
of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-
host disease. Blood 109, 4097–4104.
Yamanishi, Y., Kitaura, J., Izawa, K., Kaitani, A., Komeno, Y., Nakamura, M.,
Yamazaki, S., Enomoto, Y., Oki, T., Akiba, H., et al. (2010). TIM1 is an endog-
enous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney
ischemia/reperfusion injury. J. Exp. Med. 207, 1501–1511.
Yao, S., Zhu, Y., Zhu, G., Augustine, M., Zheng, L., Goode, D.J., Broadwater,
M., Ruff, W., Flies, S., Xu, H., et al. (2011). B7-H2 is a costimulatory ligand for
CD28 in human. Immunity 34, in press. 10.1016/j.immuni.2011.03.014.
Yu, X., Harden, K., Gonzalez, L.C., Francesco, M., Chiang, E., Irving, B., Tom,
I., Ivelja, S., Refino, C.J., Clark, H., et al. (2009). The surface protein TIGIT
suppresses T cell activation by promoting the generation of mature immuno-
regulatory dendritic cells. Nat. Immunol. 10, 48–57.
Zhang, X., Voskens, C.J., Sallin, M., Maniar, A., Montes, C.L., Zhang, Y., Lin,
W., Li, G., Burch, E., Tan, M., et al. (2010). CD137 promotes proliferation
and survival of human B cells. J. Immunol. 184, 787–795.
Zhou, Z., Pollok, K.E., Kim, K.K., Kim, Y.J., and Kwon, B.S. (1994). Functional
analysis of T-cell antigen 4-1BB in activated intestinal intra-epithelial T
lymphocytes. Immunol. Lett. 41, 177–184.
Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J.,
Zheng, X.X., Strom, T.B., and Kuchroo, V.K. (2005). The Tim-3 ligand galec-
tin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245–
1252.
